Affiliation:
1. Department of Hematology, “Carol Davila” University of Medicine and Pharmacy, 030167 Bucharest, Romania
2. Fundeni Clinical Institute, 022328 Bucharest, Romania
Abstract
The treatment paradigm of multiple myeloma (MM) has shifted in the past years, as continuous therapy is becoming the standard of care for both newly diagnosed and relapsed patients. Although it is indisputable that continuous therapy has added a great benefit on the progression-free as well as overall survival, it is still unclear what the patients’ perspective is on this therapeutic approach. Methods: This study included 155 adult MM patients from Fundeni Clinical Institute in Romania, receiving continuous therapy with daratumumab, proteasome inhibitors, immunomodulators, or bi-specific antibodies. The patients had varied economic, social, and educational backgrounds. We developed a questionnaire to interrogate the quantitative and qualitative effect of the therapy on the patients’ personal and professional life and to identify the side effects that had the strongest impact on their quality of life. Results: 74.83% of the patients reported that the treatment they received negatively impacted their quality of life. Among them, 40% considered that the most detrimental aspects of the therapy are the financial burden and the negative impact on their professional life. One-third of the patients reported that the therapy negatively impacted their personal life and that it had a deleterious effect on their relationship with their partner and family members. In terms of the side effects experienced, patients considered that tiredness was the main factor causing a decrease in their quality of life, followed by insomnia and bone pain. Despite this, almost none of the patients considered dropping the therapy, and almost half of the patients considered that the frequent visits to the hospital offered them psychological comfort. In addition, more than 70% of the patients declared that they were afraid to stop the therapy if given the choice, with the main concerns being the fear of an early relapse. Conclusions: Although continuous therapy is associated with a high financial burden and a negative impact on both professional and personal life, the frequent visits to the hospital appear to be reassuring. Moreover, the patients would not opt for treatment discontinuation and felt safer when monitored frequently.
Funder
University of Medicine and Pharmacy
Reference38 articles.
1. Eisfeld, C., Kajüter, H., Möller, L., Wellmann, I., Shumilov, E., and Stang, A. (2023). Time trends in survival and causes of death in multiple myeloma: A population-based study from Germany. BMC Cancer, 23.
2. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008
3. Emerging immunotherapies in multiple myeloma;Shah;BMJ,2020
4. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management;Rajkumar;Am. J. Hematol.,2022
5. Moving Toward Continuous Therapy in Multiple Myeloma;Bonello;Clin. Hematol. Int.,2019